RQM+ Appoints Ross D. Segan, MD, MBA, FACS, to Board of Directors

RQM+, a leading global MedTech service provider (CRO), today announced that Ross D. Segan, M.D., MBA, FACS, has joined its board of directors. Dr. Segan is a physician–executive and MedTech strategist with senior leadership experience at the U.S. Food and Drug Administration (FDA), Johnson & Johnson, Olympus, Covidien, and Vensana Capital, and currently serves as CEO of Medical Scientific Advisors, LLC.

“Dr. Segan’s leadership at the intersection of clinical practice, regulatory science, and global MedTech innovation is unmatched,” said John Potthoff, Ph.D., chief executive officer of RQM+. “His experience advising regulators, industry leaders, and investors will strengthen RQM+’s ability to help clients navigate complexity and deliver high-impact products to market.”

“RQM+’s clear sense of purpose and respect for the trust placed in our industry by patients and regulators drew me to the board,” said Dr. Segan. “I look forward to contributing my experience to a company that sees quality and regulatory excellence as enablers of lasting impact.”

Michael Farah, partner at Linden Capital, said, “At Linden, we invest in leadership and governance to drive long-term value, and Dr. Segan exemplifies that approach. His experience across clinical care, regulation, and enterprise strategy will be a strong asset as RQM+ continues to scale its platform and impact.”

Dr. Segan’s career spans 20+ clinical specialties and global markets, with a consistent focus on aligning clinical outcomes, regulatory strategy, health economics, and reimbursement to unlock commercial value. He is also active in policy and advocacy through work with AdvaMed and other industry organizations.

About RQM+

RQM+ is a leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product life cycle.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Holly Haynes today!